A Single Center, Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate the safety, Tolerability, and Pharmacokinetics of SUVN-D4010 after Single Ascending Doses and Multiple Ascending Doses in Healthy Male Subjects

Trial Profile

A Single Center, Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate the safety, Tolerability, and Pharmacokinetics of SUVN-D4010 after Single Ascending Doses and Multiple Ascending Doses in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs SUVN D4010 (Primary)
  • Indications Alzheimer's disease; Schizophrenia
  • Focus Adverse reactions
  • Sponsors Suven Life Sciences
  • Most Recent Events

    • 20 Jul 2017 Results of two phase I studies including this study presented at the Alzheimer's Association International Conference 2017.
    • 03 Jun 2016 Status changed from recruiting to completed.
    • 19 Oct 2015 Results presented at the annual meeting of the Society for Neuroscience (SFN) 2015, as per Suven Life Science media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top